| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/14/2011 | WO2011044001A1 Compounds and compositions as modulators of gpr119 activity |
| 04/14/2011 | WO2011043630A2 Composition for preventing and treating obesity diseases containing highly water-soluble 2-hydroxypropyl-β-cyclodextrin as active ingredient |
| 04/14/2011 | WO2011043590A2 Pharmaceutical composition for treating diabetes or hypertension using taxus cuspidata and mulberry tree extracts, and method for preparing same |
| 04/14/2011 | WO2011043568A2 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
| 04/14/2011 | WO2011043530A1 Glp-1 analog fusions, and composition for preventing or treating diabetes containing the fusions as an active ingredient |
| 04/14/2011 | WO2011043453A1 Activator for peroxisome proliferator activated receptor |
| 04/14/2011 | WO2011043371A1 Oxazole compound |
| 04/14/2011 | WO2011043237A1 Agent for ameliorating type-2 diabetes, and food or beverage containing same |
| 04/14/2011 | WO2011042890A2 Use of phenolic compounds for protein deglycolysation |
| 04/14/2011 | WO2011042765A1 Inorganic salt complexes of vildagliptin |
| 04/14/2011 | WO2011042474A1 Novel estrogen receptor ligands |
| 04/14/2011 | WO2011042465A1 Sulfonamides for the prevention of diabetes |
| 04/14/2011 | WO2011041897A1 Compositions and methods for the transport of therapeutic agents |
| 04/14/2011 | WO2011021203A3 Desferrioxamine-metal complexes for the treatment of immune-related disorders |
| 04/14/2011 | WO2010137979A3 Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercaemia |
| 04/14/2011 | WO2010137875A3 Composition containing a bean extract for improving blood circulation and increasing vascular health |
| 04/14/2011 | WO2008031501A3 2-phenoxy nicotine acid derivative and use thereof |
| 04/14/2011 | US20110088128 Polypeptide extracted from plants of the genus lupinus or produced in recombinant form, nucleotide sequence encoding it and its use in animal nutrition, as a plant growth promoter and in the fight against pathogenic fungi |
| 04/14/2011 | US20110086919 High eicosapentaenoic acid producing strains of yarrowia lipolytica |
| 04/14/2011 | US20110086895 Thiazolidinedione energy restriction-mimetic agents |
| 04/14/2011 | US20110086889 Tetrazole compounds as orexin receptor antagonists |
| 04/14/2011 | US20110086885 Indole-2-carboxylic acid amides |
| 04/14/2011 | US20110086880 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/14/2011 | US20110086863 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 04/14/2011 | US20110086857 N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| 04/14/2011 | US20110086856 Compositions useful as inhibitors of protein kinases |
| 04/14/2011 | US20110086849 novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and ause thereof |
| 04/14/2011 | US20110086846 Azaindazole Compounds As CCR1 Receptor Antagonists |
| 04/14/2011 | US20110086836 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators |
| 04/14/2011 | US20110086829 Compositions and methods for treating obesity |
| 04/14/2011 | US20110086815 Novel compositions containing xanthohumol-cyclodextrin complexes |
| 04/14/2011 | US20110086809 Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development |
| 04/14/2011 | US20110086105 Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation |
| 04/14/2011 | US20110086096 Modified release 1- [ (3-hydroxy-adamant-1-ylamino)-acetyl] -pyrrolidine-2 (s) -carbonitrile formulation |
| 04/14/2011 | US20110086093 Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| 04/14/2011 | US20110086074 Combinations of niacin and an oxicam |
| 04/14/2011 | US20110086050 Glycoprotein compositions |
| 04/14/2011 | US20110086045 Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract |
| 04/14/2011 | US20110086031 Inhibition Of The Activity Of The Capsaicin Receptor In The Treatment Of Obesity Or Obesity-Related Diseases And Disorders |
| 04/14/2011 | US20110086015 Zinc finger nuclease for the cftr gene and methods of use thereof |
| 04/14/2011 | US20110086003 Stabilization of hydrophobic protein therapeutic agents |
| 04/14/2011 | US20110083984 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis |
| 04/14/2011 | CA2780295A1 Compositions and methods for treating obesity |
| 04/14/2011 | CA2777406A1 Thiazolidinedione energy restriction-mimetic agents |
| 04/14/2011 | CA2777108A1 Sulphone compounds and methods of making and using same |
| 04/14/2011 | CA2777096A1 Compositions and methods for the transport of therapeutic agents |
| 04/14/2011 | CA2776021A1 Sulfonamides for the prevention of diabetes |
| 04/14/2011 | CA2776005A1 Inorganic salt complexes of vildagliptin |
| 04/14/2011 | CA2774573A1 Compounds and compositions as modulators of gpr119 activity |
| 04/14/2011 | CA2774133A1 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
| 04/13/2011 | EP2309261A1 Methods for evaluating tissue morphogenesis and morphogenic activity |
| 04/13/2011 | EP2308963A2 System for processing lipoaspirate cells |
| 04/13/2011 | EP2308892A1 Use of siRNA targetting Sipa1l1 for the reduction of adipogenesis |
| 04/13/2011 | EP2308880A1 Tetracyclic compound |
| 04/13/2011 | EP2308878A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments |
| 04/13/2011 | EP2308861A1 Macrocyclic compounds useful as pharmaceuticals |
| 04/13/2011 | EP2308855A1 2,4-Diaminopyrimidine derivatives |
| 04/13/2011 | EP2308851A1 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes |
| 04/13/2011 | EP2308847A1 Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
| 04/13/2011 | EP2308846A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308845A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308844A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308840A1 GPCR agonists |
| 04/13/2011 | EP2308838A1 Nitrogen-containing aromatic heterocyclyl compound |
| 04/13/2011 | EP2308828A2 CaSR antagonist |
| 04/13/2011 | EP2308562A2 Azetidine ring compounds and drugs comprising the same |
| 04/13/2011 | EP2308499A1 Bifidobacterium longum ATCC BAA-999 (BL999) and weight control |
| 04/13/2011 | EP2308496A2 Formulation containing phosphate derivatives of electron transfer agents |
| 04/13/2011 | EP2308493A1 Ameliorating or therapeutic agent for dyslipidemia |
| 04/13/2011 | EP2308486A1 Pufa supplements |
| 04/13/2011 | EP2308485A1 Sulfonamides for the prevention of diabetes |
| 04/13/2011 | EP2308481A1 Combination therapy for the treatment of hypertension |
| 04/13/2011 | EP2308473A1 Pharmaceutical composition containing surface-coated microparticles |
| 04/13/2011 | EP2308320A2 Hydroxypropylated starch for preventing/treating diabetes |
| 04/13/2011 | EP2307544A2 Genetic component of complications in type 2 diabetes |
| 04/13/2011 | EP2307422A1 Novel spirochromanone carboxylic acids |
| 04/13/2011 | EP2307411A1 Triazolopyridine compounds useful as kinase inhibitors |
| 04/13/2011 | EP2307379A2 Organic compounds |
| 04/13/2011 | EP2307047A2 Respiratory syncytial virus renders dendritic cells tolerogenic |
| 04/13/2011 | EP2307044A1 Orally administrable dosage forms comprising angiogenin and uses thereof |
| 04/13/2011 | EP2307038A2 Therapeutic agents comprising elastin-like peptides |
| 04/13/2011 | EP2307030A1 Composition comprising 1, 3 /1, 6 beta glucan for reducing weight |
| 04/13/2011 | EP2307023A1 Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| 04/13/2011 | EP2306982A1 Pharmaceutical compositions of rosuvastatin calcium |
| 04/13/2011 | EP1713779B1 Indazole derivatives as inhibitors of hormone-sensitive lipases |
| 04/13/2011 | EP1542978B1 Novel bio-active molecules |
| 04/13/2011 | EP1539763B1 Azaindole kinase inhibitors |
| 04/13/2011 | CN1993122B Cholesterol lowering supplement and low cholesterol egg produced by using the same |
| 04/13/2011 | CN1939296B Theapolyphenol composition and its preparation |
| 04/13/2011 | CN1926109B Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| 04/13/2011 | CN1723019B Compounds having anti-proliferative properties |
| 04/13/2011 | CN102015761A GLP-1 peptide having sugar chain attached thereto |
| 04/13/2011 | CN102015746A Compositions comprising galactomannan and a process thereof |
| 04/13/2011 | CN102015712A Heterocyclic compounds as adenosine receptor antagonist |
| 04/13/2011 | CN102015677A Pyrimidinone derivatives and methods of use thereof |
| 04/13/2011 | CN102015676A Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators |
| 04/13/2011 | CN102015668A Piperazine derivatives and their use as leptin receptor modulators |
| 04/13/2011 | CN102015641A Heterocyclic compound |
| 04/13/2011 | CN102015638A Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient |
| 04/13/2011 | CN102015637A Novel phenylpyrrole derivative |